+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Coronary Syndrome - Global Strategic Business Report

  • PDF Icon

    Report

  • 182 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227823
The global market for Acute Coronary Syndrome was estimated at US$9.7 Billion in 2024 and is projected to reach US$17.6 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Acute Coronary Syndrome market.

Acute Coronary Syndrome - Key Trends and Drivers

Acute Coronary Syndrome (ACS) is a critical condition that encompasses a spectrum of heart-related issues arising from the sudden reduction of blood flow to the heart muscle. This spectrum includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). The primary underlying cause of ACS is the rupture or erosion of atherosclerotic plaques within the coronary arteries, leading to thrombus (blood clot) formation that partially or fully obstructs the artery. This obstruction compromises oxygen delivery to the heart muscle, causing ischemia and, if untreated, can lead to myocardial infarction (heart attack). Patients typically present with symptoms such as chest pain or discomfort, which may radiate to the arm, neck, jaw, or back, as well as shortness of breath, sweating, nausea, and dizziness. Early and accurate diagnosis is crucial and is typically achieved through a combination of clinical evaluation, electrocardiograms (ECGs), blood tests for cardiac biomarkers like troponins, and imaging studies such as echocardiography or coronary angiography.

Treatment strategies for ACS are aimed at quickly restoring blood flow, minimizing heart muscle damage, and preventing further complications. Pharmacological interventions include antiplatelet agents (e.g., aspirin and P2Y12 inhibitors), anticoagulants (e.g., heparin), beta-blockers, nitrates, and statins, which collectively help in stabilizing the plaque, reducing clot formation, managing symptoms, and preventing further cardiovascular events. For patients with severe artery blockage or ongoing chest pain, interventional procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are employed. PCI, which often involves the placement of drug-eluting stents, has become a cornerstone in ACS management due to its efficacy in reducing restenosis (re-narrowing of the artery). Advances in these interventional techniques, along with the development of new antiplatelet and anticoagulant medications, have significantly improved survival rates and outcomes for ACS patients. Post-acute management includes lifestyle modifications, cardiac rehabilitation, and long-term medication adherence to mitigate the risk of recurrent events.

The growth in the ACS market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases is a major driver, largely due to aging populations and lifestyle-related risk factors such as obesity, physical inactivity, poor diet, smoking, and the rising incidence of diabetes and hypertension. Secondly, advancements in diagnostic technologies are enabling earlier and more precise detection of ACS. High-sensitivity cardiac biomarkers and advanced imaging techniques like cardiac MRI and CT angiography allow for timely and accurate diagnosis, which is critical for effective intervention. Thirdly, the continuous development of novel therapeutic agents and sophisticated interventional procedures is expanding the arsenal of treatment options, thereby improving patient outcomes and driving market growth. Additionally, there is a growing awareness and education about cardiovascular health, which is encouraging more individuals to seek medical attention at the early onset of symptoms, thus increasing the demand for ACS-related healthcare services. Government initiatives and funding focused on enhancing cardiovascular care infrastructure and research are also bolstering the market. Lastly, the integration of telemedicine and digital health solutions is enhancing patient monitoring and follow-up care, enabling better management of ACS and contributing to overall market expansion. These digital advancements allow for remote patient monitoring, timely medical interventions, and improved adherence to treatment regimens, further driving the growth of the ACS market.

Scope of Study:

The report analyzes the Acute Coronary Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:
  • Segments: Segment (Acute Coronary Syndrome)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $2.6 Billion in 2024, and China, forecasted to grow at an impressive 16.2% CAGR to reach $4.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Acute Coronary Syndrome Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Acute Coronary Syndrome Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Acute Coronary Syndrome Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Biological E. Ltd., Daiichi Sankyo Co., Ltd. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 62 companies featured in this Acute Coronary Syndrome market report include:

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Acute Coronary Syndrome - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
  • Aging Population Throws the Spotlight on Growing Incidence of ACS
  • Rising Rates of Obesity and Diabetes Propel Growth in ACS Cases
  • Advances in Diagnostic Technologies Spur Adoption of Early Detection Methods
  • Development of High-Sensitivity Cardiac Biomarkers Strengthens Business Case for Precise Diagnosis
  • Innovations in Imaging Techniques Improve ACS Detection
  • Enhanced Antiplatelet and Anticoagulant Therapies Generate Demand for Advanced Treatment Options
  • Integration of Drug-Eluting Stents in PCI Procedures Drives Adoption of Interventional Treatments
  • Increased Awareness and Education on Heart Health Propel Growth in Preventive Measures
  • Advances in Telemedicine and Digital Health Solutions Aid Better ACS Management
  • Expansion of Cardiac Rehabilitation Programs Drives Demand for Post-Treatment Services
  • Increasing Utilization of Artificial Intelligence in ACS Diagnosis and Treatment
  • Focus on Reducing Hospital Readmission Rates Strengthens Business Case for Effective ACS Management
  • Adoption of Mobile Health Applications for Heart Monitoring Drives Market Growth
  • Expansion of Healthcare Services in Emerging Markets Expands Addressable Market for ACS Solutions
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Acute Coronary Syndrome Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 5: USA Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 6: USA Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • CANADA
  • TABLE 7: Canada Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 8: Canada Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • JAPAN
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 9: Japan Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 10: Japan Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • CHINA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 11: China Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 12: China Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • EUROPE
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 13: Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 14: Europe Historic Review for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 15: Europe 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 16: France Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 17: France Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • GERMANY
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 18: Germany Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 19: Germany Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • ITALY
  • TABLE 20: Italy Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Italy Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • UNITED KINGDOM
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 22: UK Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 23: UK Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • SPAIN
  • TABLE 24: Spain Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Spain Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • RUSSIA
  • TABLE 26: Russia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Russia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF EUROPE
  • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Rest of Europe Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • ASIA-PACIFIC
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 31: Asia-Pacific Historic Review for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 32: Asia-Pacific 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 33: Australia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 34: Australia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • INDIA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 35: India Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: India Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • SOUTH KOREA
  • TABLE 37: South Korea Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 38: South Korea Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF ASIA-PACIFIC
  • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 40: Rest of Asia-Pacific Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • LATIN AMERICA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 41: Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: Latin America Historic Review for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Latin America 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
  • TABLE 44: Argentina Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Argentina Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • BRAZIL
  • TABLE 46: Brazil Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Brazil Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • MEXICO
  • TABLE 48: Mexico Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Mexico Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF LATIN AMERICA
  • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Rest of Latin America Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • MIDDLE EAST
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 52: Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 53: Middle East Historic Review for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 54: Middle East 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
  • TABLE 55: Iran Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 56: Iran Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • ISRAEL
  • TABLE 57: Israel Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 58: Israel Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • SAUDI ARABIA
  • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Saudi Arabia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • UNITED ARAB EMIRATES
  • TABLE 61: UAE Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 62: UAE Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF MIDDLE EAST
  • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 64: Rest of Middle East Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • AFRICA
  • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 65: Africa Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Africa Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

Table Information